Skip to main content
Clinical Trials/JPRN-jRCT2090220288
JPRN-jRCT2090220288
Completed
Phase 2

Clinical trials for the verification of safety and efficiency of tamibarotene for the treatment of Alzheimer's disease - Clinical trials of tamibarotene for Alzheimer's disease

Fumihiko Yasuno0 sites50 target enrollmentApril 13, 2017

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Alzheimer's disease
Sponsor
Fumihiko Yasuno
Enrollment
50
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 13, 2017
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Fumihiko Yasuno

Eligibility Criteria

Inclusion Criteria

  • The patients of Alzheimer's disease with mild and moderate cognitive disfunction(15\<MMSE score\<27\)

Exclusion Criteria

  • The use of other drugs of clinical trials

Outcomes

Primary Outcomes

Not specified

Similar Trials